

# A Murine Model for Human Sepiapterin-Reductase Deficiency

Seungkyoung Yang,<sup>1,3,\*</sup> Young Jae Lee,<sup>3,\*</sup> Jin-Man Kim,<sup>2</sup> Sean Park,<sup>3</sup> Joanna Peris,<sup>5</sup> Philip Laipis,<sup>4</sup> Young Shik Park,<sup>6</sup> Jae Hoon Chung,<sup>1</sup> and S. Paul Oh<sup>3</sup>

<sup>1</sup>Department of Biological Sciences, Korea Advanced Institute of Science and Technology, and <sup>2</sup>Department of Pathology, Chungnam National University School of Medicine, Daejeon, South Korea; Departments of <sup>3</sup>Physiology and Functional Genomics and <sup>4</sup>Biochemistry and Molecular Biology, University of Florida College of Medicine, and <sup>5</sup>Department of Pharmacodynamics, University of Florida College of Pharmacy, Gainesville; and <sup>6</sup>School of Biotechnology and Biomedical Science, Inje University, Kimhae, South Korea

Tetrahydrobiopterin (BH<sub>4</sub>) is an essential cofactor for several enzymes, including all three forms of nitric oxide synthases, the three aromatic hydroxylases, and glyceryl-ether mono-oxygenase. A proper level of BH<sub>4</sub> is, therefore, necessary for the metabolism of phenylalanine and the production of nitric oxide, catecholamines, and serotonin. BH<sub>4</sub> deficiency has been shown to be closely associated with diverse neurological psychiatric disorders. Sepiapterin reductase (SPR) is an enzyme that catalyzes the final step of BH<sub>4</sub> biosynthesis. Whereas the number of cases of neuropsychological disorders resulting from deficiencies of other catalytic enzymes involved in BH<sub>4</sub> biosynthesis and metabolism has been increasing, only a handful of cases of SPR deficiency have been reported, and the role of SPR in BH<sub>4</sub> biosynthesis *in vivo* has been poorly understood. Here, we report that mice deficient in the *Spr* gene (*Spr*<sup>-/-</sup>) display disturbed pterin profiles and greatly diminished levels of dopamine, norepinephrine, and serotonin, indicating that SPR is essential for homeostasis of BH<sub>4</sub> and for the normal functions of BH<sub>4</sub>-dependent enzymes. The *Spr*<sup>-/-</sup> mice exhibit phenylketonuria, dwarfism, and impaired body movement. Oral supplementation of BH<sub>4</sub> and neurotransmitter precursors completely rescued dwarfism and phenylalanine metabolism. The biochemical and behavioral characteristics of *Spr*<sup>-/-</sup> mice share striking similarities with the symptoms observed in SPR-deficient patients. This *Spr* mutant strain of mice will be an invaluable resource to elucidate many important issues regarding SPR and BH<sub>4</sub> deficiencies.

Tetrahydrobiopterin (BH<sub>4</sub>) is an essential cofactor for multiple enzymes, including phenylalanine-4-hydroxylase (PAH), tyrosine-3-hydroxylase (TH [MIM 191290]), tryptophan-5-hydroxylase (TPH [MIM 191060]), all three forms of nitric oxide synthase (NOS1 [MIM 163731], NOS2 [MIM 163730], and NOS3 [MIM 163729]), and glyceryl-ether mono-oxygenase (Thöny et al. 2000; Blau et al. 2001*b*). Deficiencies in BH<sub>4</sub> metabolism can affect the function of all these enzymes, leading to a variety of metabolic syndromes. For example, PAH converts phenylalanine to tyrosine in the liver, which is the first step in phenylalanine degradation. When PAH is missing or defective, phenylalanine may reach levels of  $\geq 1$  mM in the blood, leading to phenylketonuria (PKU [MIM 261600]) (Scriver and Kaufman 2001). These levels result in severe damage to early brain development unless strict dietary restriction of phenylalanine is instituted. Lower levels of phenylalanine (0.12–0.99 mM; termed “hyperphenylalaninemia”) are usually considered benign, although dietary modification may be considered at higher levels in this range (Huttenlocher 2000; Scriver and Kaufman 2001). PKU (or “variant PKU”) can also be caused by defects in BH<sub>4</sub> biosynthesis (Blau et al. 1992; Thöny and Blau 1997; Thöny et al.

1998*a*, 1998*b*). Recent studies have shown that PKU-affected patients with certain BH<sub>4</sub> deficiencies as well as PAH mutations benefitted from the supplementation of BH<sub>4</sub> (Spaapen and Rubio-Gozalbo 2003; Fiege et al. 2005). In addition, TH and TPH are rate-limiting enzymes for the production of the biogenic amine neurotransmitters dopamine, norepinephrine, and serotonin (Fitzpatrick 1999). Deficiencies in TH or TPH have been implicated in recessive Segawa syndrome (MIM 605407), familial infantile parkinsonism (MIM 168600), and unipolar major depression (MIM 608516) (Ludecke et al. 1995, 1996; Swaans et al. 2000). BH<sub>4</sub> deficiency can present with similar phenotypes (Blau et al. 2001*b*). Nitric oxide (NO) is synthesized by the three forms of NOS (NOS1–NOS3) and has a variety of physiological roles (Mungrue et al. 2003). Deficiencies in NOS function in human patients because of BH<sub>4</sub> biosynthetic defects have not been carefully examined but may well exist.


BH<sub>4</sub> homeostasis is regulated by the *de novo* biosynthesis pathway, as well as by the salvage pathway and the *de novo* regeneration pathway (fig. 1A). BH<sub>4</sub> is synthesized from guanosine triphosphate (GTP) through a cascade of enzymatic modifications (Thöny et al. 2000;

Received October 21, 2005; accepted for publication January 17, 2006; electronically published January 31, 2006.

Address for correspondence and reprints: Dr. S. Paul Oh, Department of Physiology and Functional Genomics, University of Florida, 1600 SW Archer Road, Room D533d, Gainesville, FL 32610. E-mail: ohp@phys.med.ufl.edu

\* These two authors contributed equally to this work.

*Am. J. Hum. Genet.* 2006;78:575–587. © 2006 by The American Society of Human Genetics. All rights reserved. 0002-9297/2006/7804-0006\$15.00



**Figure 1** Biosynthesis of BH<sub>4</sub> and generation of *Spr*-knockout mice. **A**, Biosynthesis of BH<sub>4</sub>, including the possible alternative pathways (dashed arrows). **B**, Mouse *Spr* genomic structure (wild-type), the knockout (KO) construct, and the resulting targeted mutant allele. The *Spr* gene consists of three exons. Blackened and unblackened boxes represent exons that encode translated and untranslated regions of SPR, respectively. Restriction-enzyme sites for *Eco*RI (E), *Hind*III (H), *Nco*I (N), and *Sac*I (S) are indicated. Restriction-enzyme sites in parentheses indicate the loss of a recognition sequence during construction of the KO vector. The probes (5' probe and 3' probe) for Southern-blot analysis and the expected sizes of fragments from wild-type and mutant *Spr* loci are shown. To construct the targeting vector, a segment from exon 1 and the entire exon 2 region were replaced with the PGK-neomycin resistance cassette (PGK-Neo). The herpes simplex virus–thymidine kinase cassette (HSV-TK) was inserted at the 3' end of the construct, for negative selection by FIAU. **C**, Southern-blot analysis of embryonic stem cell clones by use of the 5' probe. Genomic DNA isolated from embryonic stem cell clones was digested with *Eco*RI. The 5' probe detects the *Spr* pseudogene (>12 kb) as well as the wild-type (9.5 kb) and mutant (4.4 kb) bands in the authentic *Spr* locus. **D**, Southern-blot analysis of pups from *Spr*<sup>+/-</sup> matings by use of the 3' probe. Genomic DNA from pups was digested with *Nco*I. Southern-blot analysis using the authentic *Spr* gene-specific 3' probe showed 13.3-kb and 9.9-kb bands for the wild-type and mutant alleles, respectively. **E**, Northern-blot analysis showing no detectable *Spr* transcript in the kidney of *Spr*<sup>-/-</sup> mice.

Blau et al. 2001a, 2001b). The first step of de novo biosynthesis is the conversion of GTP to D-erythro-7,8-dihydroneopterin triphosphate, which is mediated by GTP cyclohydrolase I (GTPCH [MIM 600225]). This reaction is thought to be the rate-limiting step in de novo biosynthesis. D-erythro-7,8-dihydroneopterin triphosphate is then converted to 6-pyruvoyl-tetrahydropterin (PTP) by 6-pyruvoyl-tetrahydropterin synthase (PTPS [MIM 261640]) and subsequently to BH<sub>4</sub> by sepiapterin reductase (SPR [MIM 182125]) through reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction steps 1–3 (fig. 1A). Although SPR is known to be the major enzyme in these final reduction steps, aldo-keto reductases (AKR) and carbonyl reduc-

tases (CBR) can also convert PTP to BH<sub>4</sub>. AKR can convert PTP to 1'-oxo-2'-hydroxy tetrahydropterin (1'-oxo-TP) (Milstien and Kaufman 1989; Levine et al. 1990) and can also reduce 1'-hydroxy-2'-oxo-tetrahydropterin (2'-oxo-TP) to BH<sub>4</sub> (Park et al. 1991). CBR can convert PTP to 1'-oxo-TP or to 2'-oxo-TP (Park et al. 1991). Therefore, in the presence of both AKR and CBR, BH<sub>4</sub> can be synthesized from PTP without SPR. Bonafe et al. (2001) showed greatly reduced BH<sub>4</sub> levels in the cerebrospinal fluid (CSF) of human patients with SPR deficiency, indicating that such pathways indeed exist and partially compensate for the lack of SPR in vivo. However, a detailed assessment of this compensatory activity in various organ systems has been lacking.

In the salvage pathway, sepiapterin is formed non-enzymatically from 1'-oxo-TP and is converted to 7,8-dihydrobiopterin (BH<sub>2</sub>) by SPR (step 4 in fig. 1). BH<sub>2</sub> is then reduced to BH<sub>4</sub> by dihydrofolate reductase (DHFR [MIM 126060]). During the conversion of phenylalanine to tyrosine by PAH, BH<sub>4</sub> is oxidized to pterin-4 $\alpha$ -carbinolamine (Fitzpatrick 1999). Pterin-4 $\alpha$ -carbinolamine dehydratase (PCD [MIM 126090]) converts pterin-4 $\alpha$ -carbinolamine to q-dihydrobiopterin, which is regenerated to BH<sub>4</sub> by dihydropteridine reductase (DHPR [MIM 261630]). The regeneration of BH<sub>4</sub> from pterin-4 $\alpha$ -carbinolamine is important because it supplies BH<sub>4</sub> and removes the harmful metabolites produced by pterin-4 $\alpha$ -carbinolamine (Thöny et al. 2000).

Genetic mutations of all the enzymes involved in BH<sub>4</sub> homeostasis have been shown to cause BH<sub>4</sub> deficiencies (Thöny et al. 2000; Blau et al. 2001a, 2001b). BH<sub>4</sub> deficiencies manifest very heterogeneous symptoms, depending on individual mutations and other modifying genes. In general, patients with BH<sub>4</sub> deficiency exhibit progressive neuronal deterioration, mental retardation, convulsions, disturbances of tone and posture, abnormal movements, hypersalivation, swallowing difficulties, and temperature instability (Blau et al. 1996). BH<sub>4</sub> deficiencies can be broadly divided into two groups, depending on the presence of a PKU phenotype. Individuals harboring two mutant alleles in *GTPCH*, *PTPS*, *DHFR*, and *PCD* display symptoms accompanied by a varying (mild to severe) degree of PKU (Blau et al. 2001b), whereas dominantly inherited *GTPCH* deficiency manifests as dopa-responsive dystonia (MIM 128230) without PKU (Blau et al. 2001a).

*SPR* deficiency in a human patient was not reported until 2001, and thus it had been believed that the absence of *SPR*-deficient patients might have been because of the presence of compensatory pathways via *AKR* and *CBR* (fig. 1A) and because *SPR* is dispensable for BH<sub>4</sub> biosynthesis in vivo. Since 2001, when a new diagnostic method for detecting *SPR* enzyme activity in cultured fibroblasts from patients was developed, 15 patients with *SPR* deficiency have been reported (Bonafe et al. 2001; Elzaouk et al. 2002; Neville et al. 2005; Tetrahydrobiopterin Web site). These patients with *SPR* deficiency were initially misdiagnosed as having *DHPR* deficiency. The pterin metabolic profiles of two patients with *SPR* mutations described by Bonafe et al. (2001) showed differences between brain and peripheral tissues. Bonafe et al. (2001) suggested that these differences might be the result of different levels of enzymes (i.e., *AKR*, *CBR*, and *DHFR*) playing a compensatory role for the lack of *SPR*. These results indicate that *SPR* is indeed essential for BH<sub>4</sub> homeostasis and that a better understanding of the in vivo role of *SPR* in the regulation of BH<sub>4</sub> homeostasis would be helpful for the correct diagnosis of *SPR* deficiency.

To investigate the role of *SPR* in the regulation of BH<sub>4</sub> homeostasis and in BH<sub>4</sub> deficiency, we generated a mouse strain deficient in the *Spr* gene by the gene-targeting technique. *Spr*-deficient mice (*Spr*<sup>-/-</sup>) were born normal, but they developed dwarfism during the early postnatal period. *Spr*<sup>-/-</sup> mice appeared to have greatly reduced levels of BH<sub>4</sub> in the brain and liver. Dopamine and serotonin levels were also significantly reduced in the relevant brain areas, and the mice displayed impaired locomotion activities. Interestingly, unlike results for human patients, the serum phenylalanine level in the *Spr*<sup>-/-</sup> mice was greatly increased. Dwarfism and high serum phenylalanine levels could be completely reversed by oral supplementation of BH<sub>4</sub> and neurotransmitter precursors. This *Spr* mutant strain will be an invaluable resource to uncover many important issues regarding *SPR* and BH<sub>4</sub> deficiencies.

## Material and Methods

The *Spr*-knockout mouse strain was generated at the University of Florida. The mice were maintained under standard specific-pathogen-free conditions, and all animal procedures performed were reviewed and approved by the University of Florida Institutional Animal Care and Use Committee.

### Generation of *Spr*-Knockout Mice

The mouse *Spr* gene encodes 261 aa and consists of three exons (fig. 1B) (Ota et al. 1995; Lee et al. 1999). We had previously isolated a phage clone containing the entire *Spr* gene from a 129/SvJ (129) mouse genomic DNA library (Lee et al. 1999). To construct a targeting vector, a 3.3-kb *Hind*III-*Sac*I fragment including a part of exon 1 and a 3.8-kb *Sac*I-*Hind*III fragment containing the exon 3 region were sequentially inserted into the *Xho*I and *Xba*I sites, respectively, of the pPNT vector (Tybulewicz et al. 1991). The phosphoglycerate kinase (PGK)-neomycin cassette replaced a portion of exon 1, intron 1, and the entire exon 2 encoding the short-chain dehydrogenase/reductase domain. After electroporation of the linearized construct, G418-resistant and 1-(2-deoxy-2-fluoro-1- $\beta$ -D-arabinofuranosyl)-5-iodouracil (FIAU)-resistant colonies were selected. Approximately 300 double-resistant colonies were screened by Southern-blot analysis using a 5' external probe (5' probe in fig. 1B). One of the three positive clones was microinjected into C57BL/6J (B6) blastocysts to generate chimeras, which were crossed with B6 mice to establish and maintain the *Spr*<sup>+/-</sup> mouse line on a mixed 129/B6 hybrid background. The genotype of offspring from the breeding of heterozygous mice was determined with PCR primer sets *Spr*F1 (5'-AAGTGGTGCTGGCAGCCGCCGAT-3') and *Neo*P3 (5'-CGGTGCTGTCCATCTGCACGAGAC-3'), for detection of the mutant allele, and *srex*2F (5'-CCTCCATGCTCTGTTGACT-3') and *srex*2R (5'-GTTCCCTCCTGCCTAGC-3'), for detection of the wild-type allele. The genomic region amplified by the *srex*2F and *srex*2R primer set was deleted in the mutant allele, and thus no PCR amplification occurs for the *Spr*<sup>-/-</sup> mice.

### Southern-Blot Analysis

DNA extracted from embryonic stem cells and mouse tails was digested with *EcoRI* or *NcoI*, run on a 0.8% agarose gel, blotted onto Gene Screen plus membrane, and hybridized with the radiolabeled 5' probe (for *EcoRI*-digested DNA) or 3' probe (for *NcoI*-digested DNA) (fig. 1B).

### Northern-Blot Analysis

Total RNA was isolated from the kidney and the brain with a Trizol reagent (Invitrogen). A sample of 7  $\mu\text{g}$  of kidney RNA or 20  $\mu\text{g}$  of brain RNA was used for Northern-blot analysis (Pelle and Murphy 1993) with the *Spr* or *Th* cDNA probe, respectively.

### Replacement Therapy

Replacement therapy was performed in accord with the method described by Elzaouk et al. (2003). To prepare the low-dose solution, 390 mg of  $\text{BH}_4\text{-2HCl}$  (Schircks Laboratories), 300 mg of ascorbic acid (Sigma), 44.4 mg of 5-hydroxytryptophan (Sigma), 15 mg of carbidopa (Sigma), and 150 mg of *N*-acetyl-L-cysteine (Sigma) were dissolved in 5 ml of  $\text{H}_2\text{O}$ . Dopa solution was prepared by dissolving 63.6 mg of L-dopa (Sigma) in 1 ml of 0.5 N HCl. The two solutions were mixed and adjusted to pH 5.0 with sodium citrate. To prepare the high-dose solution, 780 mg of  $\text{BH}_4\text{-2HCl}$ , 600 mg of ascorbic acid, 57 mg of 5-hydroxytryptophan, 15 mg of carbidopa, and 300 mg of *N*-acetyl-L-cysteine were dissolved in 5 ml of  $\text{H}_2\text{O}$ . Dopa solution was prepared by dissolving 81 mg of L-dopa in 1 ml of 0.5 N HCl. The two solutions were mixed and adjusted to pH 5.0 with sodium citrate and then were frozen until use. The mixed solution (500  $\mu\text{l}$  per kg body weight) was administered orally twice a day by use of micropipettes.

### Preparation of Mouse Tissues for Pteridine Measurement

The brain and liver were removed immediately after each mouse was sacrificed and were blended in a cold homogenizing buffer containing 50 mM Tris-HCl (pH 7.5), 0.1 M KCl, 1 mM EDTA, 1 mM dithiothreitol, and proteinase inhibitors (EDTA-free proteinase inhibitor cocktail [Roche]) by use of an electric homogenizer (Biospec Products). For the brain tissue, 4  $\mu\text{l}/\text{mg}$  of the homogenizing buffer was added, and, for the liver, 5  $\mu\text{l}/\text{mg}$  was added. Homogenates were centrifuged at 15,000 g for 20 min at 4°C, and supernatants were kept frozen at -80°C.

### Neopterin, Biopterin, and $\text{BH}_4$ Measurements

The  $\text{BH}_4$  level was measured using high-performance liquid chromatography (HPLC) analysis after iodine oxidation in acidic or alkaline conditions, as described elsewhere (Fiege et al. 2004). To measure the amount of neopterin and biopterin, a volume of either 100  $\mu\text{l}$  of liver or brain homogenates was used for acidic (or basic) oxidation, followed by the addition of 100  $\mu\text{l}$  of 0.2 N HCl (or NaOH). The homogenate was then incubated in the dark for 1 h, after 10  $\mu\text{l}$  of acidic iodine solution was added (0.9% iodine and 1.8% potassium iodine in 0.1 N HCl [or NaOH]). The reaction was terminated by addition of 10  $\mu\text{l}$  of 5% ascorbic acid. Oxidized samples were

filtered using an Ultra-free MC filter (10,000-MW cutoff [Millipore]). The filtrates were subjected to HPLC analysis (using Waters 600E Pump). Concentrations are expressed as pmol per mg of protein.  $\text{BH}_4$  levels were derived by subtracting biopterin levels under a basic oxidative state (biopterin +  $\text{BH}_2$ ) from the levels under an acidic oxidative state (i.e., total biopterin = biopterin +  $\text{BH}_2$  +  $\text{BH}_4$ ). The separation was performed on a Spherisorb ODS1 C18 (particle size 5  $\mu\text{m}$ ; length  $\times$  internal diameter = 250  $\times$  4.6 mm; Waters) by use of 1 mM potassium phosphate (pH 4.6) with 5% (v/v) methanol at a flow rate of 0.6 ml/min. Pterins were detected by their native fluorescence (excitation wavelength 350 nm; emission wavelength 450 nm) by use of a 2475 fluorescence detector (Waters).

### Sepiapterin Measurement

Tissue homogenates were filtered with an Ultrafree-MC filter (10,000-MW cutoff [Millipore]) and were subjected to HPLC. The separation was performed on a precolumn (Symmetry C8 [5  $\mu\text{m}$ ; 20  $\times$  3.9 mm; Waters]) and an analytical column (Symmetry C8 [5  $\mu\text{m}$ ; 150  $\times$  4.6 mm; Waters]) by use of the method described by Zorzi et al. (2002), with some modifications. The compositions of solvents A and B for gradient elution were isopropanol:methanol:acetic acid: $\text{H}_2\text{O}$  (0.5:0.5:0.5:98.95 [v/v]) for solvent A and isopropanol:methanol:acetic acid (49:49:2 [v/v]) for solvent B. The flow rate was maintained at 0.6 ml/min by use of the following gradient program: solvent A at 100% for 3.4 min, solvent B at 0%–2% for 8.5 min, solvent B at 2% for 3.4 min, solvent B at 2%–20% for 17 min, solvent B at 20% for 1.7 min, solvent B at 40% for 8.5 min, and solvent A at 100% for 17 min.

### Measurement of Catecholamines, Serotonin, and Other Related Metabolites

Dopamine, norepinephrine, 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin, and 5-hydroxyindole acetic acid (HIAA) levels in several brain regions were measured by HPLC with electrochemical detection (Blau et al. 1999). The frontal cortex, caudate putamen, cerebellum, and general area of the cortex were separated from the brain and were immediately frozen in liquid  $\text{N}_2$ . Tissue samples were maintained at -80°C until the neurotransmitters and their metabolites were measured. Tissue was weighed with a minimum of thawing and was then homogenized in 2 ml of 0.1 N perchloric acid by use of a Brinkmann Homogenizer. The homogenate was centrifuged at 7,360 g for 20 min. The supernatant was filtered through a 0.22- $\mu\text{m}$  filter and was injected onto the HPLC column (YMC-Pac Pro C18 [5  $\mu\text{m}$ ; 250  $\times$  4.6 mm; YMC]). The column was connected to an HP 3390A integrator maintained at 0.5–1.0 mA and to an LDC/Milton Roy Minipump. The mobile phase consisted of 12.5 mM citric acid, 7.5 mM sodium phosphate (monobasic), 0.2 mM  $\text{Na}_2\text{EDTA}$ , 0.15 mM sodium octyl sulfate (35 mg/liter), and 3.5% acetonitrile. The mobile phase was then passed through a 0.22- $\mu\text{m}$  filter (Micron Separations) before being degassed under helium for at least 15 min. All separations were performed at a flow rate of 2.22 ml/min. The amounts of neurotransmitters and their metabolites in each sample were normalized for the weight of the brain tissue from which they were extracted.

### Microplate Serum Phenylalanine Assay

Serum phenylalanine was measured using a fluorimetric assay (McCaman and Robins 1962) modified for small volumes and microtiter plate format. In the assay, 7.5  $\mu$ l of serum was precipitated with 11.2  $\mu$ l of 0.3 N trichloroacetic acid and were chilled on ice for 10 min. Using a 96-well PCR plate, 64  $\mu$ l of assay cocktail were dispensed into each well. The cocktail contained 4.40 ml of 0.3 M succinate (pH 5.8), 1.76 ml of 30 mM ninhydrin, and 0.880 ml of 5 mM L-leucyl-L-alanine. Standards were prepared from 10 mM phenylalanine in 0.3 N trichloroacetic acid. Each standard and sample was run in triplicate. Four microliters of each standard was added to three wells spaced across the microtiter plate. The precipitated serum samples were centrifuged at 16,000 g for 10 min in a microcentrifuge. From each sample, 4  $\mu$ l of the supernatant was added to three consecutive wells, and the plate was capped and incubated in a thermocycler at 60°C for 2 h. Copper reagent (200  $\mu$ l; 15 mM Na<sub>2</sub>CO<sub>3</sub>, 2.3 mM potassium sodium tartrate, and 2.4 mM CuSO<sub>4</sub>·5H<sub>2</sub>O) was added to each well of a 96-well 0.5-ml black fluorimeter plate (Nunc). Additional copper reagent (100  $\mu$ l) was added to the incubated samples in the PCR plate, and then the entire volume was transferred into the fluorimeter plate. The PCR plate was washed with another 100  $\mu$ l of copper reagent, and the wash was added to the fluorimeter plate. The plate was read twice on an FLx800 Multidetector Microplate Reader (BioTek) with excitation filter of 380 nm and emission filter of 508 nm. Both readings were averaged to calculate the phenylalanine concentration in each serum sample relative to the standard curve.

### Immunohistochemistry

Dopaminergic and noradrenergic neural cell bodies are located in the substantia nigra, ventral tegmental area, and locus ceruleus. The animals were anaesthetized with ketamine, and perfusion fixation was performed by perfusing transcardially with ice-cold 10% neutral buffered formalin for 10 min at a flow rate of 30–40 ml/min. The brains of the animals were immediately removed and then were fixed in the same solution overnight. The fixed tissues were embedded in paraffin. Coronal sections (3- $\mu$ m thick) and parasagittal sections (3- $\mu$ m thick) were used for the evaluation of immunoreactivities. Immunohistochemical staining was performed using EnVision anti-mouse or anti-rabbit kits (DAKO). Heat-induced antigen retrieval was required. The sections were placed in a pressure cooker for 4 min at maximum pressure in 10 mM citrate buffer (pH 7.0). The sections were pretreated with 0.3% H<sub>2</sub>O<sub>2</sub> in 0.1 M Tris-buffered saline (TBS) (pH 7.4) for 10 min to quench endogenous peroxidases. Anti-mouse TH (1:50 dilution [Novocastra]), anti-rabbit TPH (1:50 dilution [Novocastra]), anti-mouse calbindin (1:40 dilution [Abcam]), and anti-rabbit AADC (1:50 dilution [BIOMOL]) antibodies were used. The primary antibodies were applied and incubated for 30 min at room temperature (TH, TPH, and calbindin) or overnight at 4°C (AADC) in a humid chamber. After being washed with 0.1 M TBST (0.1 M TBS and 0.01% Tween 20), sections were incubated with EnVision anti-mouse or anti-rabbit (DAKO) polymer for 30 min. Visualization of the antibody complex was achieved by treatment with 3,3'-diaminobenzidine chro-

mogen substrate solution (DAKO) and counterstaining with Meyer's hematoxylin.

### Measurement of Insulin-Like Growth Factor 1 (IGF1)

Total IGF1 (MIM 147440) levels in the serum were measured by radioimmunoassay in accord with the method described by Breier et al. (1991). Serum samples were extracted with acid-ethanol. Then, 25  $\mu$ l of serum was treated briefly with 100  $\mu$ l of acid-ethanol (12.5% 2 N HCl and 87.5% ethanol) and was incubated for 30 min at room temperature. After centrifugation at ~6,000 g for 3 min at room temperature, 50  $\mu$ l of the clear supernatant was transferred to a new tube. The sample was then neutralized with 250  $\mu$ l of 0.855 M Tris-base and was centrifuged at 10,000 g for 10 min at 4°C. The supernatant was then assayed for the IGF1 level. To determine the recovery of IGF1 from acid-ethanol extraction, recombinant IGF1 was spiked into the mouse serum at 10, 5, and 2 ng/ml. Finally, the IGF1 concentration was calculated by radioimmunoassay. Two sets of standards were routinely included in each assay to determine IGF1 concentration calculated by a Riasmart program (Packard). The lower limit of detection for this assay was 1 ng/ml. The intra-assay and interassay coefficients of validation were 6.7% and 10.2%, respectively.

### Behavioral Test

To analyze locomotor activity, we performed two tests for voluntary movement: four-limb akinesia and turning on a screen (Szczyпка et al. 2001). In the four-limb akinesia test, the mice were picked up by the tail and were slowly placed on a surface. The amount of time required for the mice to move all four limbs was measured. In the turning test, the mice were placed head-down on a screen positioned at the edge of a countertop and tilted 60° from the surface. The amount of time required for the mice to reorient themselves in the opposite direction was measured.

## Results

### Generation of *Spr*-Knockout Mouse Line

To investigate the role of SPR in mouse development and in the biosynthesis of BH<sub>4</sub>, we generated a strain of mice deficient in the *Spr* gene, using conventional knockout technology. The mouse *Spr* gene encodes 261 aa and consists of three exons (Ota et al. 1995; Lee et al. 1999). As shown in figure 1B, a knockout construct was generated by replacing a *Spr* genomic region, including a portion of exon 1 and the entire exon 2, with the PGK-neomycin cassette. Since exon 2 encodes the short-chain dehydrogenase/reductase domain essential for SPR function and because the designed deletion leads to a frameshift in the subsequent exon 3, the *Spr*-knockout allele was expected to be null. Homologous recombination in embryonic stem cells was confirmed by genomic Southern-blot analysis. Using the 5' probe, we identified three positive embryonic stem cell clones from 300 G418- and


FIAU-resistant clones (fig. 1C). One of three correctly targeted embryonic stem cell clones was microinjected into B6 blastocysts to generate chimeras. The chimeras were crossed with B6 mice to establish and maintain the *Spr* heterozygous (*Spr*<sup>+/-</sup>) mouse line on a mixed 129/B6 hybrid background. Homozygous mice (*Spr*<sup>-/-</sup>) were obtained from heterozygote breeding. The 5' probe detects the *Spr* pseudogene (*Spr-ps1*), which lacks the promoter region and exon 3 that are present in the authentic *Spr* gene (Lee et al. 1999). Using the 3' probe, which detects the *Spr* locus but not *Spr-ps1*, we confirmed that the gene targeting was made on the authentic *Spr* locus (fig. 1D). We showed the absence of *Spr* transcripts in the kidneys of the *Spr*<sup>-/-</sup> mice by Northern-blot analysis (fig. 1E).

#### Growth Retardation and Reduced Serum IGF1 Levels in *Spr*<sup>-/-</sup> Mice

*Spr*<sup>+/-</sup> mice are viable and fertile and do not display any detectable abnormalities. *Spr*<sup>-/-</sup> mice were indistinguishable from their littermates at birth, but all *Spr*<sup>-/-</sup> mice (*n* > 60) showed discernible growth retardation within a few days after birth, and almost no gain of body weight was recorded beyond 2 wk after birth (fig. 2A and 2B). Most *Spr*<sup>-/-</sup> mice died within 1–2 mo, whereas a few survived for 2–6 mo. To test whether dwarfism was affected by littermate competition, *Spr*<sup>-/-</sup> mice were quarantined from their normal siblings. However, no significant weight gain was observed in these mice, in comparison with those kept together with their normal siblings. The growth curve of *Spr*<sup>-/-</sup> mice was remarkably similar to that of *Pts*<sup>-/-</sup> mice that were rescued by replacement therapy with high doses of BH<sub>4</sub> and neurotransmitter precursors (Elzaouk et al. 2003). Since the serum IGF1 levels were significantly reduced in the rescued *Pts*<sup>-/-</sup> mice with dwarfism, we examined the serum IGF1 levels in *Spr*<sup>-/-</sup> mice, using a radioimmunoassay. As shown in figure 2C, the serum IGF1 levels were severely reduced in *Spr*<sup>-/-</sup> mice, compared with the levels in the wild-type and *Spr*<sup>+/-</sup> littermates. This finding suggests that reduced IGF1 is a probable cause of the growth retardation in the *Spr*<sup>-/-</sup> mice.


#### Severely Impaired BH<sub>4</sub> Biosynthesis in *Spr*<sup>-/-</sup> Mice

It has been postulated that, unlike GTPCH and PTSP function, SPR function can be compensated by AKR and CBR (Milstien and Kaufman 1989; Levine et al. 1990; Park et al. 1991). However, the extent to which SPR deficiency affects BH<sub>4</sub> homeostasis in vivo has been unknown. To address this issue, we measured the neopterin, total biopterin, BH<sub>4</sub>, and sepiapterin levels in the liver and brain of 4-wk-old *Spr*<sup>+/+</sup> (wild-type), *Spr*<sup>+/-</sup>, and *Spr*<sup>-/-</sup> mice (fig. 3). Eight brain samples from each



**Figure 2** Growth of *Spr*<sup>-/-</sup> mice and serum IGF1 levels. **A**, A 45-d-old *Spr*<sup>-/-</sup> mouse with dwarfism compared with an *Spr*<sup>+/+</sup> littermate. **B**, Growth curves of *Spr*<sup>+/+</sup> (red), *Spr*<sup>+/-</sup> (blue), and *Spr*<sup>-/-</sup> (green) mice. Each line represents an individual mouse. **C**, Serum IGF1 levels. Three 4-wk-old mice of each genotype were tested. Values are means (and SE is indicated above each bar). \**P* < .01, compared with *Spr*<sup>+/+</sup> mice, as determined by Student's *t* test.

genotype of mice, six liver samples from *Spr*<sup>+/+</sup> and *Spr*<sup>+/-</sup> mice, and eight liver samples from *Spr*<sup>-/-</sup> mice were analyzed. We found a significant decrease in BH<sub>4</sub> levels in both liver and brain, but the magnitude of the decrease was different in these two organs. In the liver, the BH<sub>4</sub> level was dramatically reduced (to 1.1% of wild type) in *Spr*<sup>-/-</sup> mice compared with the controls, whereas a relatively mild decrease (40.5% of wild type) was detected in the brain of *Spr*<sup>-/-</sup> mice. We also found dramatic sepiapterin accumulation in the brain and liver of *Spr*<sup>-/-</sup> mice, compared with that found in the brains and livers of the *Spr*<sup>+/+</sup> and *Spr*<sup>+/-</sup> mice. The amount of neopterin, a 7,8-dihydroneopterin triphosphate metabolite, increased moderately in the liver (to ~3 times that found in *Spr*<sup>+/+</sup> mice) and in the brain (to 5 times). These data show that AKR and CBR partially compensate for the loss of SPR in both the brain and liver and that the brain has a greater degree of compensation than the liver does.



**Figure 3** Pteridine levels. Neopterin, total biopterin (tbiopterin), BH<sub>4</sub>, and sepiapterin levels in the liver (A) and brain (B) are shown. Six *Spr*<sup>+/+</sup>, six *Spr*<sup>+/-</sup>, and eight *Spr*<sup>-/-</sup> mice were used for the liver tests. Eight mice of each genotype were used for the brain tests. Values are means (and SE is indicated above each bar). \**P* < .001 and \*\**P* < .01, compared with *Spr*<sup>+/+</sup> mice, as determined by Student's *t* test.


### Severely Impaired Phenylalanine Metabolism and Biosynthesis of Catecholamines and Serotonin in *Spr*<sup>-/-</sup> Mice

Because BH<sub>4</sub> is an essential cofactor for PAH, TH, and TPH, we then investigated the extent to which the lowered BH<sub>4</sub> level impacted the function of these enzymes. With regard to TH and TPH enzyme activities, we measured the levels of dopamine, DOPAC (a metabolite of dopamine), and norepinephrine, for TH, and the levels of serotonin and 5-HIAA (a metabolite of serotonin), for TPH, in the caudate putamen, cortex, and cerebellum of the wild-type (*Spr*<sup>+/+</sup>), *Spr*<sup>+/-</sup>, and *Spr*<sup>-/-</sup> mice. We found that the amount of neurotransmitters (i.e., dopamine, norepinephrine, and serotonin) was markedly reduced in the relevant areas of the *Spr*<sup>-/-</sup> brain. The dopamine levels in the caudate putamen and cortex of *Spr*<sup>-/-</sup> mice was 10-fold lower than those in the caudate putamens and cortexes of *Spr*<sup>+/+</sup> and *Spr*<sup>+/-</sup> mice (fig. 4A). DOPAC in the caudate putamen and cortex was below the detection limit in *Spr*<sup>-/-</sup> mice (fig. 4B). Norepinephrine was also dramatically reduced in the cortex and cerebellum of *Spr*<sup>-/-</sup> mice (fig. 4C). The serotonin level was greatly reduced in the cortex of *Spr*<sup>-/-</sup> mice, whereas the 5-HIAA level was comparable to that in *Spr*<sup>+/+</sup> and *Spr*<sup>+/-</sup> mice (fig. 4D and 4E).

*Spr*<sup>-/-</sup> mice showed remarkably higher serum phenylalanine levels (2,732 μM; *n* = 5) than did the *Spr*<sup>+/+</sup> and *Spr*<sup>+/-</sup> controls (~63 μM; *n* = 5) (fig. 4F), and the phenylalanine levels were even higher than those of the *Pah*<sup>enu2</sup> mice (1,701 μM; *n* = 10), a PKU animal model widely used for *Pah* mutation studies (Shedlovsky et al. 1993). These data clearly demonstrate that BH<sub>4</sub> deficiency in *Spr*-knockout mice is sufficient to cause impaired activity of BH<sub>4</sub>-dependent enzymes, including TH, TPH, and PAH.

### Reduced TH Protein Level in Nerve Terminals of *Spr*<sup>-/-</sup> Mice

TH-immunoreactivity in *Pts*<sup>-/-</sup> mice declined considerably in the nerve terminals but not in the cell bodies (Sumi-Ichinose et al. 2001). As described above, the BH<sub>4</sub>




**Figure 4** Activities of TH, TPH, and PAH. To determine the TH enzyme activity, dopamine (A), DOPAC (B), and norepinephrine (C) levels were measured in the caudate putamen (CPU), cortex (CTX), and cerebellum (CBL). For TPH activity, serotonin (D) and 5-HIAA (E) levels were measured in the CTX and CBL. Three *Spr*<sup>+/+</sup>, five *Spr*<sup>+/-</sup>, and three *Spr*<sup>-/-</sup> mice were analyzed. Values are means (and SE is indicated above each bar). \**P* < .01 and \*\**P* < .05, compared with *Spr*<sup>+/+</sup> mice, as determined by Student's *t* test. F, Phenylalanine levels of 28–44-d-old mice were measured to determine the functional PAH enzyme activity. *Pah*<sup>enu2</sup> mice harbor a mutation in the *Pah* gene that is generated by *N*-ethyl-*N*-nitrosourea (ENU) mutagenesis. Five *Spr*<sup>+/+</sup> or *Spr*<sup>+/-</sup> mice (controls), 5 *Spr*<sup>-/-</sup> mice, and 10 *Pah*<sup>enu2</sup> mice were used. Values are means (and SE is indicated above each bar). \**P* < .001, compared with *Spr*<sup>+/+</sup> mice, as determined by Student's *t* test.

and dopamine levels in *Spr*<sup>-/-</sup> mice were comparable to those found in *Pts*<sup>-/-</sup> mice, and thus we examined the localization of TH proteins in cell bodies as well as in the nerve terminals of *Spr*<sup>-/-</sup> brains. Whereas TH staining in the dopaminergic cells of wild-type mouse brains stretches from the substantia nigra into the caudate putamen along the dopaminergic fibers, TH staining of the *Spr*<sup>-/-</sup> brain is strongly detected in the substantia nigra but gradually becomes faint along the dopaminergic fibers and finally disappears near the caudate putamen region (fig. 5A and 5B). The coronal sections of the brains in the striatum area further demonstrate the striking difference between the two groups. Whereas the nerve fibers were heavily stained with the TH antibody in the striatum of the wild-type brain (fig. 5C), almost no staining was detected in the corresponding region of the *Spr*<sup>-/-</sup> brain (fig. 5D). A few unusual TH-immunopositive cells (red arrowheads in fig. 5F) and weakly positive fibers (black arrowheads in fig. 5F) were found in the striatum of the *Spr*<sup>-/-</sup> brain. To test whether this difference was the result of the degeneration of dopaminergic neurons in the striatum of the *Spr*<sup>-/-</sup> brains, we stained the brains of both wild-type and *Spr*<sup>-/-</sup> mice, using aromatic amino acid decarboxylase (AADC [MIM 107930]) antibodies, which detect dopaminergic neurons. The AADC antibody-staining pattern in the striatum areas of the *Spr*<sup>-/-</sup> brain was comparable to that of the wild-type brain, indicating normal development of dopaminergic neurons in *Spr*<sup>-/-</sup> mice (fig. 5G and 5H). The immunostaining pattern using calbindin antibodies yielded the same result (data not shown). Northern-blot analysis showed normal expression of the *Th* transcript in the *Spr*<sup>-/-</sup> brain (data not shown). These data are consistent with the results in studies of *Pts*<sup>-/-</sup> mice (Sumi-Ichinose et al. 2001) and suggest that a normal level of BH<sub>4</sub> is required for the stability and/or localization of TH proteins at nerve fibers. We also stained the *Spr*<sup>-/-</sup> brain sections with TPH antibodies and found no differences in staining pattern or intensity between the mutant brains compared with controls, showing that (unlike for TPH function), the expression, stability, and localization of TPH are unaffected by the lower level of BH<sub>4</sub> (data not shown).

#### Abnormal Locomotion Activities Exhibited by *Spr*<sup>-/-</sup> Mice

Dopaminergic neurons are essential for the regulation of body movement. Dramatically reduced dopamine levels and the abnormal expression of TH in the striatum predict impairment of locomotive activities in *Spr*<sup>-/-</sup> mice. To test this, we used four-limb akinesia and turning tests to monitor voluntary movement (fig. 6). The *Spr*<sup>-/-</sup> mice scored significantly worse on both tests than did the wild-type group, a finding that presents further




**Figure 5** Expression of TH in the brain. Brain sections from *Spr*<sup>+/+</sup> (A, C, E, and G) and *Spr*<sup>-/-</sup> (B, D, F, and H) mice were immunostained with anti-TH antibody (A, B, C, D, E, and F) or anti-AADC antibody (G and H). A few unusual TH-immunopositive cells (red arrowheads) and weakly positive fibers (black arrowheads) are indicated in the caudate putamen (CPu) of the *Spr*<sup>-/-</sup> brain (F). Images E and F are magnified (×400) views of the CPu regions in images C and D (original magnification ×5), respectively. All mice were 4 wk old. SN = substantia nigra; VTA = ventral tegmental area.

evidence of dysfunction in the nigrostriatal pathway and of reduced dopamine and TH levels in the striatum of *Spr*<sup>-/-</sup> mice.

#### Restoration of *Spr*-Null Phenotypes by Oral Supplementation of BH<sub>4</sub> and Neurotransmitter Precursors

To investigate whether the supplementation of BH<sub>4</sub> and neurotransmitter precursors can rescue the growth retardation and other related phenotypes of *Spr*<sup>-/-</sup> mice, we used the same oral treatment methods and doses used by Elzaouk et al. (2003) to rescue the *Pts*<sup>-/-</sup> mice. We used only two dose ranges (designated as “high” and “low” doses; see the “Material and Methods” section



**Figure 6** Behavioral defects in *Spr*<sup>-/-</sup> mice. *A*, Four-limb akinesia test. The mice were picked up by the tail and slowly placed on a surface. The time that it took for the mice to move all four limbs was recorded. *B*, Turning test. The mice were placed head-down on a screen positioned at the edge of a countertop and tilted 60° from the surface. The time required for the mice to reorient themselves in the opposite direction was recorded. The maximum time for each set of these tests was 2 min. Four mice of each genotype were used. Values are means (and SE is indicated above each bar). \**P* ≤ .001, compared with the *Spr*<sup>+/+</sup> mice, as determined by Student's *t* test.

for details) instead of three. We administered supplements orally twice a day, beginning at the newborn stage. Body weights were recorded every day for 75 d, and the brains, livers, and serum samples were collected to measure the levels of BH<sub>4</sub> and its derivatives, IGF1, and phenylalanine after 4 wk of treatment. Figure 7 shows body weights of controls and experimental *Spr*<sup>-/-</sup> mice after 4 wk and 75 d of treatment (fig. 7*A* and 7*B*, respectively). Although *Spr*<sup>-/-</sup> mice treated with either high- or low-dose supplementation gained more body weight and developed glossier coats than did nontreated controls, those administered a low dose gained considerably less than did those given a high dose (fig. 7*A*–7*D*). The serum IGF1 level was almost completely restored in the treated mutant mice (fig. 7*E*). We also found that the phenylalanine levels in rescued *Spr*<sup>-/-</sup> mice were restored to the control level (data not shown).


In contrast to this rescue of body weight and of serum levels of IGF1 and phenylalanine by oral supplementation, there was no rescue of BH<sub>4</sub> level in the brain and little increase in BH<sub>4</sub> level in the liver, in comparison with untreated controls (table 1). In addition, we stained the high-dose-treated *Spr*<sup>-/-</sup> brain sections with TH antibodies to test whether the treatment recovered TH localization in the striatum. The brains, isolated 3 h after the administration of two high doses at once, showed no changes in the TH-staining patterns in the rescued *Spr*<sup>-/-</sup> brain compared with those of untreated controls (data not shown).

## Discussion

Here, we report the generation and characterization of mice deficient in the *Spr* gene, which is involved in BH<sub>4</sub>

biosynthesis and metabolism. We found that homeostasis of BH<sub>4</sub>, dopamine, norepinephrine, serotonin, and phenylalanine are greatly disturbed in *Spr*<sup>-/-</sup> mice, which exhibit dwarfism and impaired body movement. Oral supplementation of BH<sub>4</sub> and neurotransmitter precursors did not restore BH<sub>4</sub> levels but did completely rescue dwarfism and phenylalanine metabolism.

Pterin profile data in the liver and brain of *Spr*<sup>-/-</sup> mice showed elevated neopterin and sepiapterin as well as reduced biopterin and BH<sub>4</sub>, in comparison with the control littermates (table 1). The implications of these data are as follows. First, the BH<sub>4</sub> level was markedly reduced, but not abolished, in *Spr*<sup>-/-</sup> mice, which demonstrates that SPR is essential for BH<sub>4</sub> homeostasis in mouse tissues. This result is consistent with recent findings in SPR-deficient humans (Bonafe et al. 2001; Elzaouk et al. 2002; Tetrahydrobiopterin Web site). Second, the alternative pathway of BH<sub>4</sub> biosynthesis from PTP, most likely mediated by AKR and CBR, can only partially compensate for the role of SPR. The degree of



**Figure 7** Rescue of *Spr*<sup>-/-</sup> mice with BH<sub>4</sub> and neurotransmitter precursors. *A* and *B*, Body weights of rescued 4-wk-old mice (*A*) and 75-d-old mice (*B*). Values are means (and SE is indicated above each bar). \**P* < .01, as determined by Student's *t* test. *C* and *D*, Representative 4-wk-old rescued mice with low-dose (*C*) or high-dose (*D*) supplementation. *E*, Serum IGF1 levels in rescued mice. The nontreated group (Non) comprised three mice of each genotype; the low-dose-treated group (Low) comprised two *Spr*<sup>+/+</sup>, three *Spr*<sup>+/-</sup>, and three *Spr*<sup>-/-</sup> mice; and the high-dose-treated group (High) comprised two *Spr*<sup>+/+</sup>, two *Spr*<sup>+/-</sup>, and six *Spr*<sup>-/-</sup> mice. Serum was collected 6–8 h after the final treatment. Values are means (and SE is indicated above each bar).

**Table 1**

**Effects of Repeated Oral Administration of BH<sub>4</sub> and Neurotransmitters**

TREATMENT AND MICE	LEVEL IN BRAIN (pmol/mg of protein)				LEVEL IN LIVER (pmol/mg of protein)			
	Neopterin	Total Biopterin	BH <sub>4</sub>	Sepiapterin	Neopterin	Total Biopterin	BH <sub>4</sub>	Sepiapterin
None:								
<i>Spr</i> <sup>+/+</sup>	.17 ± .06	8.85 ± .58	5.97 ± .42	ND	.21 ± .06	43.41 ± 2.49	38.57 ± 1.80	ND
<i>Spr</i> <sup>+/-</sup>	.29 ± .04	15.81 ± .94	4.67 ± .60	ND	.35 ± .08	39.28 ± 1.87	32.36 ± 1.92	ND
<i>Spr</i> <sup>-/-</sup>	.89 ± .08	3.42 ± .40	2.42 ± .31	4.75 ± .43	.71 ± .10	1.94 ± .44	.42 ± .32	5.47 ± 1.04
Low dose:								
<i>Spr</i> <sup>+/+</sup>	.77	8.69	5.76	ND	.37 ± .04	39.44 ± 5.12	34.89 ± 5.74	ND
<i>Spr</i> <sup>+/-</sup>	.41	13.44	8.64	ND	.5 ± .07	49.23 ± 1.3	45.65 ± 1.19	ND
<i>Spr</i> <sup>-/-</sup>	.91 ± .16	6.30 ± 2.34	.58 ± .05	6.22 ± .88	.5	1.89	.33	9.05
High dose:								
<i>Spr</i> <sup>+/+</sup>	.2 ± .03	8.99 ± .33	7.24 ± .42	ND	.33 ± .01	41.41 ± 2.71	36.92 ± 4.16	ND
<i>Spr</i> <sup>+/-</sup>	.36 ± .22	8.58 ± 1.01	6.50 ± 2.01	ND	.31 ± .06	48.90 ± 1.62	45.64 ± 1.34	ND
<i>Spr</i> <sup>-/-</sup>	.53 ± .06	4.00 ± 1.17	1.77 ± .37	5.68 ± .58	.34 ± .03	3.82 ± 1.1	1.86 ± .60	8.72 ± .46

NOTE.—ND = not detectable.

BH<sub>4</sub> reduction in the liver and brain was significantly different—that is, there was more reduction in the liver than in the brain. This result is consistent with differences in pterin profiling among the brain (CSF), peripheral tissues, and fibroblasts of SPR-deficient patients (Bonafe et al. 2001). Such a variance is likely the result of different expression and activities of the enzymes involved in the alternative pathway of BH<sub>4</sub> biosynthesis (i.e., AKR and CBR) and the salvage pathway (i.e., CBR and DHFR) among different organs and tissues. It may also be the result of greater use of BH<sub>4</sub> in the liver for conversion of phenylalanine to tyrosine from dietary phenylalanine. Third, the sepiapterin level was significantly elevated in the liver and brain of *Spr*<sup>-/-</sup> mice, which suggests that SPR is the major reductase from sepiapterin to BH<sub>2</sub> in the salvage pathway (fig. 1A). To date, eight SPR-deficient patients' pterin profiles are available (Bonafe et al. 2001; Elzaouk et al. 2002; Tetrahydrobiopterin Web site). The sepiapterin level was reported for two of these patients, both of whom showed a high level. This elevated level of sepiapterin could be a signature of the pterin profile in SPR deficiency.

We found dramatically reduced levels of dopamine, norepinephrine, and serotonin in the relevant brain areas of *Spr*<sup>-/-</sup> mice, suggesting that the enzymatic functions of TH and TPH were severely compromised in these mutant mice. We also showed, using anti-TH immunostaining, that TH localization was normal in the cell body (substantia nigra) but undetectable in the projected nerve terminals (caudate putamen) of *Spr*<sup>-/-</sup> mice (fig. 5). Northern-blot analysis showed no differences in the TH transcript level among different genotypes. This result is in accordance with that obtained from *Pts*<sup>-/-</sup> mice (Sumi-Ichinose et al. 2001) and suggests that a normal BH<sub>4</sub> level is required for the subcellular localization and/

or stability of TH proteins in dopaminergic neurons. BH<sub>4</sub> was reported to prevent the nitration of tyrosine residues on TH mediated by reactive oxygen species (ROS) such as peroxynitrite or nitrogen dioxide (Kuhn and Geddes 2003). Such protein modifications by ROS are known to be irreversible (Agar and Durham 2003), and nitrated TH has reduced function and stability (Kuhn and Geddes 2003). It was also reported that low levels of BH<sub>4</sub> can produce ROS rather than NO. Altogether, we postulate that reduced BH<sub>4</sub> in the striatum of *Spr*<sup>-/-</sup> mice elevates ROS and reduces the prevention of nitration on TH, which in turn decreases the stability and function of TH. In contrast, whereas serotonin levels were severely reduced, TPH enzyme appeared at normal levels in the *Spr*<sup>-/-</sup> brain sections. This may suggest that—although the reduction in amine neurotransmitters such as serotonin, norepinephrine, and dopamine might be in part the result of high serum phenylalanine levels interfering with either amino acid transport in the brain or the activities of the two biosynthetic enzymes—different modes of regulation may be employed for the enzyme activities of TH and TPH, as proposed by Sumi-Ichinose et al. (2001).

*Spr*<sup>-/-</sup> mice exhibited severe dwarfism from the early postnatal period. The growth curve of *Spr*<sup>-/-</sup> mice is similar, if not identical, to that of *Pts*<sup>-/-</sup> mice supplemented with the “high” dose (Elzaouk et al. 2003). IGF1 has been shown to play a pivotal role in body growth (Liu et al. 1993, 1998; Powell-Braxton et al. 1993). Rescued *Pts*<sup>-/-</sup> mice as well as *Spr*<sup>-/-</sup> mice showed significantly reduced serum IGF1, which suggests a causative relationship between IGF1 deficiency and growth retardation in these mutant mice. It has been shown, in D2 dopamine receptor-deficient mice, that dopamine is an essential factor for growth-hormone release (Brambilla

et al. 1997; Diaz-Torga et al. 2002). In the absence of the dopamine signal, growth hormone and hypothalamic growth-hormone-releasing hormone (GHRH)-induced IGF1 production is impaired, resulting in dwarfism. Elzaouk et al. (2003) have shown normal growth hormone and thyroxine levels in the rescued *Pts*<sup>-/-</sup> mice and have suggested chronic malnutrition (due to swallowing difficulties or reduced appetite) as a potential cause of the IGF1 deficiency and dwarfism. Our *Spr*<sup>-/-</sup> mice exhibited low dopamine and IGF1 levels that were comparable to those of the rescued *Pts*<sup>-/-</sup> mice. Interestingly, oral supplementation completely rescued the dwarfism phenotype of *Spr*<sup>-/-</sup> mice and restored the IGF1 level, without any apparent change in BH<sub>4</sub> levels. At least one SPR-deficient patient displayed growth retardation (Bonafe et al. 2001). Since the fostering environments for mice and humans are obviously different, it remains to be investigated whether growth retardation is a common feature of SPR deficiency between these two species. More detailed studies are also required for deciphering the signaling pathway from lowered dopamine to lowered IGF1 for the dwarfism phenotype of the *Spr* mutants.

The *Spr*<sup>-/-</sup> serum contained a high level of phenylalanine that exceeded the levels found in *Pah*<sup>enu2</sup> mice, a PKU mouse model (Shedlovsky et al. 1993). SPR-deficient patients displayed abnormal responses in the phenylalanine loading test, indicating that the PAH function is somewhat impaired, yet the phenylalanine levels in these patients appeared to be normal (Bonafe et al. 2001). This suggests that the lowered BH<sub>4</sub> is sufficient for PAH function in the liver of SPR-deficient patients to maintain the normal phenylalanine homeostasis. The reason for this discrepancy between SPR-deficient patients and *Spr*<sup>-/-</sup> mice is unknown. One simple explanation is that mice and humans have different levels of the alternative enzyme activities that compensate for the loss of SPR, so a higher level of BH<sub>4</sub> (a level sufficient for the function of PAH) is produced in human livers than in mouse livers. Alternatively, a higher metabolic rate in mice than in humans (Terpstra 2001) may lead to faster exhaustion of BH<sub>4</sub> in mouse livers. Nonetheless, our data raise some caution about classifying SPR deficiency as a “BH<sub>4</sub>-deficiency without PKU” until consistent data are established from a larger patient pool.

We have shown, using the four-limb akinesia and turning tests, that *Spr*<sup>-/-</sup> mice displayed impaired body movement. Additionally, the prolonged crouching posture and the neglect of grooming habits demonstrated by the mice indicated depression and social detachment. The *Spr*<sup>-/-</sup> mice also displayed a tremor phenotype, a symptom associated with dystonia and Parkinson disease. Although these symptoms could be the result of small body mass and muscle weakness, the behavioral characteristics observed in *Spr*<sup>-/-</sup> mice share striking

similarities with the symptoms observed in SPR-deficient patients, who present psychomotor retardation, spasticity, dystonia, tremors, and growth retardation (Bonafe et al. 2001; Elzaouk et al. 2002; Neville et al. 2005; Tetrahydrobiopterin Web site). Patients with dystonia present dopamine deficiency and locomotive impairment while their dopaminergic neurons are intact. The same phenomenon was observed in *Spr*<sup>-/-</sup> mice. In a previous study, movement abnormalities observed in a 15-year-old SPR-heterozygous patient developed into dystonia and tremor 8 years later (Steinberger et al. 2004), which suggests that *Spr*<sup>+/-</sup> mice may also exhibit dystonic symptoms in the future; 1-year-old *Spr*<sup>+/-</sup> mice are normal, but it is possible that they will develop additional symptoms. In addition, SPR was recently reported to be associated with the *PARK3* locus, which is associated with early-onset Parkinson disease (Karamohamed et al. 2003). Consequently, the fact that a 15-year-old SPR-heterozygous patient developed a tremor and that SPR is included in the *PARK3* locus suggests that SPR may be involved in modulating the age at onset of Parkinson disease.

We succeeded in rescuing phenotypes observed in *Spr*<sup>-/-</sup> mice with the high dose of BH<sub>4</sub> and neurotransmitter precursors. After the treatment, the body weight and serum IGF1 and phenylalanine levels of the mice were restored to normal. TH expression in the brain, however, remained the same after 4 wk of either high- or low-dose treatment. In addition, both high- and low-dose treatment resulted in a prolonged average lifespan. We have observed normal behavior, vitality, and fertility in 8-mo-old *Spr*<sup>-/-</sup> mice treated with the high dose. It would be of great interest to investigate the change in the biochemical and behavioral characteristics of the rescued *Spr*<sup>-/-</sup> mice after cessation of the supplementation. It would also be fascinating to examine whether dopamine alone, without BH<sub>4</sub> and serotonin, can produce complete or partial rescue of the *Spr* mutant phenotypes.

Recently, *hpb-1* mice, in which the GTPCH activity is partially impaired, displayed pulmonary arterial hypertension (MIM 178600) with decreased NOS3 activity in the lungs (Khoo et al. 2005; Nandi et al. 2005). Because of technical limitations, we have not studied NO and NOS activities in the *Spr* mutant. Our *Spr* knockout mice would be an additional animal model for studying the impact of lowered BH<sub>4</sub> biosynthesis on NOS functions and pulmonary hemodynamics.

We believe that the *Spr*-knockout mice, as well as tissue-specific conditional *Spr*-knockout mice and transgenic mice expressing *Spr* in specific tissues for rescue experiments, will be an invaluable resource to address many important questions regarding SPR and BH<sub>4</sub> deficiencies. Such studies would provide crucial information not only for better diagnostic criteria and treatment options for human SPR deficiency but also for a broad

field of neuropathogenesis, including neurotransmitter disorders, dopamine-responsive dystonia, mental retardation, PKU, and Parkinson disease.

## Acknowledgments

We thank Dr. E. Li for J1 embryonic stem cell lines, Dr. Ed Grace for technical assistance, and Marya Park for editorial assistance. This study was supported in part by National Institutes of Health grant HL64024 (to S.P.O.) and by Basic Research Program of Korea Science and Engineering Foundation grant R01-2004-000-10128-0 (to J.H.C.).

## Web Resources

The URLs for data presented herein are as follows:

Online Mendelian Inheritance in Man (OMIM), <http://www.ncbi.nlm.nih.gov/Omim/> (for TH, TPH, NOS1, NOS2, NOS3, PKU, Segawa syndrome, Parkinson disease, major depression, GTPCH, PTPS, SPR, DHFR, PCD, DHPD, dopa-responsive dystonia, IGF1, AADC, and pulmonary arterial hypertension)

Tetrahydrobiopterin Web site, <http://www.BH4.org/>

## References

Agar J, Durham H (2003) Relevance of oxidative injury in the pathogenesis of motor neuron diseases. *Amyotroph Lateral Scler Other Motor Neuron Disord* 4:232–242

Blau N, Barnes I, Dhondt JL (1996) International database of tetrahydrobiopterin deficiencies. *J Inher Metab Dis* 19:8–14

Blau N, Bonafe L, Thöny B (2001a) Tetrahydrobiopterin deficiencies without hyperphenylalaninemia: diagnosis and genetics of dopa-responsive dystonia and sepiapterin reductase deficiency. *Mol Genet Metab* 74:172–185

Blau N, Heizmann CW, Sperl W, Korenke GC, Hoffmann GF, Smooker PM, Cotton RG (1992) Atypical (mild) forms of dihydropteridine reductase deficiency: neurochemical evaluation and mutation detection. *Pediatr Res* 32:726–730

Blau N, Thöny B, Cotton RG, Hyland K (2001b) Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) *The metabolic and molecular bases of inherited disease*. Vol. II. McGraw-Hill, New York, pp 1725–1776

Blau N, Thöny B, Renneberg A, Penzien JM, Hyland K, Hoffmann GF (1999) Variant of dihydropteridine reductase deficiency without hyperphenylalaninaemia: effect of oral phenylalanine loading. *J Inher Metab Dis* 22:216–220

Bonafe L, Thöny B, Penzien JM, Czarnecki B, Blau N (2001) Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. *Am J Hum Genet* 69:269–277

Brambilla F, Bellodi L, Perna G, Arancio C, Bertani A (1997) Dopamine function in obsessive-compulsive disorder: growth hormone response to apomorphine stimulation. *Biol Psychiatry* 42:889–897

Breier BH, Gallaher BW, Gluckman PD (1991) Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. *J Endocrinol* 128:347–357

Diaz-Torga G, Feierstein C, Libertun C, Gelman D, Kelly MA, Low MJ, Rubinstein M, Becu-Villalobos D (2002) Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice. *Endocrinology* 143:1270–1279

Elzaouk L, Leimbacher W, Turri M, Ledermann B, Burki K, Blau N, Thöny B (2003) Dwarfism and low insulin-like growth factor-1 due

to dopamine depletion in *Pts<sup>-/-</sup>* mice rescued by feeding neurotransmitter precursors and H4-biopterin. *J Biol Chem* 278:28303–28311

Elzaouk L, Osmani H, Romstad A, Friedman J, Maccollin M, Thöny B, Blau N (2002) Sepiapterin reductase deficiency: molecular analysis in a new case presenting with neurotransmitter deficiency without hyperphenylalaninemia. In: Milstien S, Kapatos G, Shane B, Levine RA (eds) *Chemistry and biology of pteridines and folates*. Kluwer Academic Publishers, Norwell, MA, pp 277–285

Fiege B, Ballhausen D, Kierat L, Leimbacher W, Goriounov D, Schircks B, Thöny B, Blau N (2004) Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. *Mol Genet Metab* 81:45–51

Fiege B, Bonafe L, Ballhausen D, Baumgartner M, Thöny B, Meili D, Fiori L, Giovannini M, Blau N (2005) Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. *Mol Genet Metab* 86:91–95

Fitzpatrick PF (1999) Tetrahydropterin-dependent amino acid hydroxylases. *Annu Rev Biochem* 68:355–381

Huttenlocher PR (2000) The neuropathology of phenylketonuria: human and animal studies. *Eur J Pediatr Suppl* 2 159:S102–S106

Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH, Lazzarini AM, et al (2003) A haplotype at the *PARK3* locus influences onset age for Parkinson's disease: the GenePD study. *Neurology* 61:1557–1561

Khoj JP, Zhao L, Alp NJ, Bendall JK, Nicoli T, Rockett K, Wilkins MR, Channon KM (2005) Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. *Circulation* 111:2126–2133

Kuhn DM, Geddes TJ (2003) Tetrahydrobiopterin prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide. *Mol Pharmacol* 64:946–953

Lee SW, Park IY, Hahn Y, Lee JE, Seong CS, Chung JH, Park YS (1999) Cloning of mouse sepiapterin reductase gene and characterization of its promoter region. *Biochim Biophys Acta* 1445:165–171

Levine RA, Kapatos G, Kaufman S, Milstien S (1990) Immunological evidence for the requirement of sepiapterin reductase for tetrahydrobiopterin biosynthesis in brain. *J Neurochem* 54:1218–1224

Liu JL, Grinberg A, Westphal H, Sauer B, Accili D, Karas M, LeRoith D (1998) Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice. *Mol Endocrinol* 12:1452–1462

Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A (1993) Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). *Cell* 75:59–72

Ludecke B, Dworniczak B, Bartholome K (1995) A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. *Hum Genet* 95:123–125

Ludecke B, Knappskog PM, Clayton PT, Surtees RAH, Clelland JD, Heales SJR, Brand MP, Bartholome K, Flatmark T (1996) Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. *Hum Mol Genet* 5:1023–1028

McCaman MW, Robins E (1962) Fluorimetric method for the determination of phenylalanine in serum. *J Lab Clin Med* 59:885–890

Milstien S, Kaufman S (1989) Immunological studies on the participation of 6-pyruvoyl tetrahydropterin (2'-oxo) reductase, an aldose reductase, in tetrahydrobiopterin biosynthesis. *Biochem Biophys Res Commun* 165:845–850

Mungrue IN, Bredt DS, Stewart DJ, Husain M (2003) From molecules to mammals: what's NOS got to do with it? *Acta Physiologica Scandinavica* 179:123–135

Nandi M, Miller A, Stidwill R, Jacques TS, Lam AA, Haworth S, Heales S, Vallance P (2005) Pulmonary hypertension in a GTP-cyclohydrolase 1-deficient mouse. *Circulation* 111:2086–2090

Neville BG, Parascandolo R, Farrugia R, Felice A (2005) Sepiapterin

- reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. *Brain* 128:2291–2296
- Ota A, Ichinose H, Nagatsu T (1995) Mouse sepiapterin reductase: an enzyme involved in the final step of tetrahydrobiopterin biosynthesis. Primary structure deduced from the cDNA sequence. *Biochim Biophys Acta* 1260:320–322
- Park YS, Heizmann CW, Wermuth B, Levine RA, Steinerstauch P, Guzman J, Blau N (1991) Human carbonyl and aldose reductases: new catalytic functions in tetrahydrobiopterin biosynthesis. *Biochem Biophys Res Commun* 175:738–744
- Pelle R, Murphy NB (1993) Northern hybridization: rapid and simple electrophoretic conditions. *Nucleic Acids Res* 21:2783–2784
- Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA (1993) IGF-I is required for normal embryonic growth in mice. *Genes Dev* 7:2609–2617
- Scriver CR, Kaufman S (2001) Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) *The metabolic and molecular bases of inherited disease*. Vol. II. McGraw-Hill, New York, pp 1667–1724
- Shedlovsky A, McDonald JD, Symula D, Dove WF (1993) Mouse models of human phenylketonuria. *Genetics* 134:1205–1210
- Spaapen LJ, Rubio-Gozalbo ME (2003) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, state of the art. *Mol Genet Metab* 78:93–99
- Steinberger D, Blau N, Goriunov D, Bitsch J, Zuker M, Hummel S, Müller U (2004) Heterozygous mutation in 5'-untranslated region of sepiapterin reductase gene (*SPR*) in a patient with dopa-responsive dystonia. *Neurogenetics* 5:187–190
- Sumi-Ichinose C, Urano F, Kuroda R, Ohye T, Kojima M, Tazawa M, Shiraiishi H, Hagino Y, Nagatsu T, Nomura T, Ichinose H (2001) Catecholamines and serotonin are differently regulated by tetrahydrobiopterin—a study from 6-pyruvoyltetrahydropterin synthase knockout mice. *J Biol Chem* 276:41150–41160
- Szczyzka MS, Kwok K, Brot MD, Marck BT, Matsumoto AM, Donahue BA, Palmiter RD (2001) Dopamine production in the caudate putamen restores feeding in dopamine-deficient mice. *Neuron* 30:819–828
- Terpstra AH (2001) Differences between humans and mice in efficacy of the body fat lowering effect of conjugated linoleic acid: role of metabolic rate. *J Nutr* 131:2067–2068
- Thöny B, Auerbach G, Blau N (2000) Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochem J* 347:1–16
- Thöny B, Blau N (1997) Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase genes. *Hum Mutat* 10:11–20
- Thöny B, Neuheiser F, Kierat L, Blaskovics M, Arn PH, Ferreira P, Rebrin I, Ayling J, Blau N (1998a) Hyperphenylalaninemia with high levels of 7-biopterin is associated with mutations in the *PCBD* gene encoding the bifunctional protein pterin-4 $\alpha$ -carbinolamine dehydratase and transcriptional coactivator (DCoH). *Am J Hum Genet* 62:1302–1311
- Thöny B, Neuheiser F, Kierat L, Rolland MO, Guibaud P, Schlüter T, Germann R, Heidenreich RA, Duran M, de Klerk JB, Ayling JE, Blau N (1998b) Mutations in the pterin-4 $\alpha$ -carbinolamine dehydratase (*PCBD*) gene cause a benign form of hyperphenylalaninemia. *Hum Genet* 103:162–167
- Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the *c-abl* proto-oncogene. *Cell* 65:1153–1163
- Zorzi G, Redweik U, Trippe H, Penzien JM, Thöny B, Blau N (2002) Detection of sepiapterin in CSF of patients with sepiapterin reductase deficiency. *Mol Genet Metab* 75:174–177